Viyash Scientific (VIYASH) Stock Overview
Operates in the veterinary healthcare business in Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VIYASH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Viyash Scientific Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹196.06 |
| 52 Week High | ₹257.85 |
| 52 Week Low | ₹117.35 |
| Beta | 0.84 |
| 1 Month Change | -4.37% |
| 3 Month Change | -6.50% |
| 1 Year Change | 43.93% |
| 3 Year Change | 166.93% |
| 5 Year Change | -12.49% |
| Change since IPO | 9.29% |
Recent News & Updates
Does Viyash Scientific (NSE:VIYASH) Deserve A Spot On Your Watchlist?
Feb 13
Is Sequent Scientific (NSE:SEQUENT) Using Too Much Debt?
Jan 04There's Reason For Concern Over Sequent Scientific Limited's (NSE:SEQUENT) Massive 27% Price Jump
Nov 20Recent updates
Does Viyash Scientific (NSE:VIYASH) Deserve A Spot On Your Watchlist?
Feb 13Is Sequent Scientific (NSE:SEQUENT) Using Too Much Debt?
Jan 04There's Reason For Concern Over Sequent Scientific Limited's (NSE:SEQUENT) Massive 27% Price Jump
Nov 20If EPS Growth Is Important To You, Sequent Scientific (NSE:SEQUENT) Presents An Opportunity
Nov 13What Sequent Scientific Limited's (NSE:SEQUENT) 27% Share Price Gain Is Not Telling You
May 15Sequent Scientific Limited's (NSE:SEQUENT) 27% Price Boost Is Out Of Tune With Revenues
May 15We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Jan 28We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Sep 27What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You
Sep 05Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)
Apr 05Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet
Mar 10Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?
Jan 31How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?
Jan 17Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?
Jan 05What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?
Dec 24Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?
Dec 12
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly
Nov 22Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)
Nov 10Shareholder Returns
| VIYASH | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.0% | 2.8% | -1.2% |
| 1Y | 43.9% | 9.2% | 7.4% |
Return vs Industry: VIYASH exceeded the Indian Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: VIYASH exceeded the Indian Market which returned 7.4% over the past year.
Price Volatility
| VIYASH volatility | |
|---|---|
| VIYASH Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: VIYASH has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: VIYASH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 1,244 | Rajaram Narayanan | www.sequent.in |
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services.
Viyash Scientific Limited Fundamentals Summary
| VIYASH fundamental statistics | |
|---|---|
| Market cap | ₹85.24b |
| Earnings (TTM) | ₹975.88m |
| Revenue (TTM) | ₹18.17b |
Is VIYASH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIYASH income statement (TTM) | |
|---|---|
| Revenue | ₹18.17b |
| Cost of Revenue | ₹8.82b |
| Gross Profit | ₹9.35b |
| Other Expenses | ₹8.38b |
| Earnings | ₹975.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.24 |
| Gross Margin | 51.46% |
| Net Profit Margin | 5.37% |
| Debt/Equity Ratio | 55.3% |
How did VIYASH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 11:52 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viyash Scientific Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nikhil Shetty | BP Wealth Management Private Limited |